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ABSTRACT  
Rationale: In early-stage breast cancer, the primary treatment option for the majority of women is 
breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess 
resection margins intraoperatively, as on average 20% of patients require further surgery to achieve 
clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by 
detecting light emitted by 18F-fluorodeoxyglucose (18F-FDG). Its high-resolution and small size 
imaging equipment makes CLI a promising technology for intraoperative margin assessment. A first-
in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative 
assessment of tumor margins in BCS. 
 
Methods: Twenty-two patients with invasive breast cancer received 5 MBq/kg 18F-FDG 45-60 min 
prior to surgery. Sentinel lymph node biopsy (SLNB) was performed using an increased technetium-
99m (99mTc)-nanocolloid activity of 150 MBq to facilitate nodal detection against the gamma-probe 
background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 
two lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an 
investigational CLI imaging system. The first 10 patients were used to optimize the imaging protocol; 
the remaining 12 patients were included in the analysis dataset. CLI images from incised BCS 
specimens were analyzed postoperatively by two surgeons blinded to the histopathology results, and 
mean radiance and margin distance were measured.  Agreement between margin distance on CLI 
and histopathology was assessed. Radiation doses to staff were measured. 
 
Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-
background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable 
margins were clear on CLI and histopathology. Agreement in margin distance and inter-rater 
agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes (SLNs) were 
successfully detected in all patients. Radiation dose to staff was low; surgeons received a mean dose 
of 34 ± 15 µSv per procedure. 
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Conclusions: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative 
assessment of tumor margins in breast-conserving surgery. A randomized controlled trial will evaluate 
the impact of this technique on re-excision rates. 
 
Key words: Cerenkov luminescence imaging; breast-conserving surgery; tumor margins; 18F-FDG; 
sentinel lymph node biopsy 
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INTRODUCTION 
In early-stage breast cancer, the primary treatment option for the majority of women is BCS by wide 
local excision (WLE) of the tumor. WLE often fails to achieve clear surgical margins, and on average 
20% of patients who undergo BCS will require repeat surgery to achieve clear margins (1) (although 
this may vary since there is no global agreement of the definition of ‘clear margins’). Re-operations 
potentially have several negative consequences including delayed commencement of adjuvant 
therapy, worse cosmesis, increased patient anxiety and costs (2,3). 
There have been several attempts to assess surgical margins intraoperatively in order to 
reduce breast cancer re-operation rates post-WLE (1). Techniques evaluated to date include 
specimen radiography, intraoperative ultrasound, touch imprint cytology, frozen section, and 
radiofrequency spectroscopy. However, these all have limitations in terms of adequate performance, 
practicality and/or cost-effectiveness (1). Experimental methods evaluated include Raman 
spectroscopy, ambient mass spectrometry, optical coherence tomography, diffuse reflectance 
spectroscopy, confocal microscopy, and (targeted) fluorescence imaging (1). Each of these 
techniques have unique limitations, and the diagnostic performance remains to be evaluated in large-
scale studies.  
Positron emission tomography (PET) using 18F-FDG is a powerful tool for in vivo imaging of 
breast cancer. While whole-body PET has limited diagnostic sensitivity for primary breast cancer, 
high-resolution PET imaging with positron emission mammography has shown high sensitivity (92-
96%) and specificity (84-91%) for breast cancer diagnosis (4-6). Intraoperative high-resolution imaging 
of 18F-FDG could therefore provide a powerful tool for surgical guidance. However, intraoperative PET 
is impractical due to the large size and expense of a PET scanner and PET’s low spatial resolution. 
Development of a compact, high-resolution, intraoperative PET scanner could address these 
limitations.  
Recently, it has been discovered that PET imaging agents emit optical photons via a 
phenomenon called Cerenkov luminescence (7). Cerenkov photons are generated by positrons 
travelling at super-relativistic speeds in tissue. Optical imaging of Cerenkov photons emitted by PET 
agents is an emerging imaging modality called CLI. CLI combines high diagnostic performance and 
clinical translatability of PET imaging with high spatial resolution and compactness of optical cameras, 
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thus making it a promising technology for intraoperative margin assessment in breast cancer surgery 
(8).  
In this first-in-human clinical trial we evaluated the feasibility, safety, and preliminary 
performance of 18F-FDG CLI using a novel intraoperative CLI camera to assess tumor margin status in 
breast cancer patients undergoing WLE with SLNB or with axillary lymph node dissection (ALND).  
 
MATERIALS AND METHODS 
Intraoperative 18F-FDG CLI in breast-conserving surgery 
     Patient recruitment and patient preparation on the day of surgery. Research Ethics Committee 
approval was obtained prior to patient recruitment (ClinicalTrials.gov identifier NCT02037269). 
Between June 2014 and February 2016, patients with histologically confirmed invasive breast cancer 
on core biopsy with or without associated ductal carcinoma in situ (DCIS), due to undergo primary 
BCS and SLNB or ALND, were recruited at Guy’s Hospital in London after written informed consent 
was obtained. Exclusion criteria were: age <30 years, previous surgery or radiotherapy to the 
ipsilateral breast in the preceding two years, neoadjuvant systemic therapy, pregnancy or lactation, 
blood glucose level of ≥12 mmol/l on the day of surgery and known hypersensitivity to 18F-FDG. 
Females of childbearing age required a negative pregnancy test (by beta HCG qualitative analysis), 
history of surgical sterilization, or history of amenorrhea in the past twelve months.   
On the day of surgery patients scheduled to undergo SLNB received a periareolar intradermal 
injection of 150 MBq 99mTc-albumin-nanocolloid (NanocollTM, GE Healthcare, UK). The increased 
99mTc activity of 150 MBq was calculated based on the results from two lead-in cross-talk studies 
(Supplemental Material). Patients were then injected intravenously with 5 MBq/kg 18F-FDG (up to a 
maximum of 300 MBq) and typically 45-60 min post-18F-FDG injection were taken to the operating 
theatre.  
 
     Surgery and intraoperative specimen radiography. Following induction of anesthesia, patients due 
to undergo SLNB received a periareolar subdermal injection of 2ml Patent Blue V and 3ml of normal 
saline. To minimize radiation exposure to theatre staff by reducing the time spent in close proximity to 
the patient, a standard breast operating set was pre-arranged on a sterile tray. Surgery to the breast 
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was performed ahead of SLNB/ALND to minimize signal intensity reduction from radiotracer decay in 
the time between 18F-FDG injection and CLI imaging. The WLE specimen was excised using 
monopolar diathermy (Valleylab Force FXTM electrosurgical generator with HCP-01 Skintact surgical 
pencil). The excised specimen was orientated with sutures and metal surgical clips as per local 
protocol.  
Post-excision WLE specimens were x-rayed intraoperatively (Faxitron Bioptics, USA), and 
excision of cavity shave margins was performed if the tumor was deemed to be close to the edge of 
the specimen on radiography.  
Following excision of the WLE specimen, SLNB or ALND was performed. For SLNB a 
Europrobe 3 gamma probe with a high-energy collimator was used (Eurorad SA, France). SLNs were 
defined as nodes that were radioactive, blue, or palpable (9). The number of excised SLNs, the ex 
vivo SLN gamma probe signal (counts per second), and the presence of blue nodal discoloration were 
recorded. Upon completion of the procedure the gamma probe background signal in the axilla was 
measured.  
 
     Intraoperative CLI of WLE specimens and lymph nodes. Following specimen radiography, CLI 
imaging of the WLE specimen was performed using an investigational intraoperative CLI imaging 
system (Lightpoint Medical Ltd, UK). This system consists of a custom-built light-tight dark box 
containing two optical pathways: one for CLI and one for white-light imaging for anatomic reference 
(Fig. 1A). The CLI imaging pathway includes a fast f/.95 lens and a reflex mirror to fold the optical 
pathway into an electron-multiplying charge coupled device (EMCCD) camera. The field-of-view of the 
CLI camera is 8×8 cm, and the acquisition matrix is 512×512 to give a pixel resolution of 156.25 µm. 
The EMCCD is thermoelectrically-cooled to -80°C and radiation-shielded with lead to prevent 
annihilation photons from scintillating in the EMCCD chip, i.e. “gamma strikes”. The white-light imaging 
pathway provides a photographic reference image using a standard complementary metal-oxide-
semiconductor camera.  
The WLE specimen was positioned on a specimen table (Fig. 1B), the margin of interest 
placed in the center of the field-of-view by using the surgical sutures to guide orientation, and 
subsequently imaged.  
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Following intact WLE specimen imaging, the surface of the specimen was immediately inked 
intraoperatively in order to preserve its orientation for histopathological analysis (Supplemental 
Material Fig. 1A). Six distinct ink colors (Davidson®, Bradley Products Inc., USA) were applied to the 
six margins. The inked specimen was then incised through the posterior margin to visualize the 
primary tumor and tumor margins, and the incised WLE specimen was imaged (Supplemental Material 
Figs. 1B and 1C). In one patient sequential image acquisition over a 50-minute time-period was 
performed to determine the half-life (t1/2) of the radiance observed in the tumor.   
The first 10 patients were included in the optimization dataset and the remaining 12 patients in 
the analysis dataset. In the first 10 patients, the image acquisition protocol was optimized by testing 
different image acquisition times (100, 300, 400 sec) and pixel binning settings (2x2, 4x4, 8x8). A 300-
sec acquisition time and 8x8 pixel binning was found to provide sufficient sensitivity for tumor 
detection and acceptable spatial resolution (1.25 mm) within a time-window feasible for intraoperative 
use, and these setting were used in the remaining 12 patients included in the analysis dataset. Upon 
completion of WLE CLI, the activity of the WLE specimen was estimated using a scintillation monitor 
(Type 41/44A, ThermoScientific, USA) or handheld radiation spectrometer (Raymon10 GR1, Kromek 
PLC). SLNs were also imaged intraoperatively with CLI using the same imaging settings.  
After imaging was completed, WLE specimens were sent for histopathological analysis as per 
standard practice. 
 
     Radiation safety monitoring. Radiation safety monitoring was performed to ensure safe working 
practices were maintained and that work was compliant with UK legislation regarding ionizing radiation 
(10-12). Prior to commencing the study all staff received training to become familiar with radiation 
control procedures, occupational risks, and learned how to minimize exposure without compromising 
patient care. Staff members were issued with electronic personal radiation dose monitors (PDM-112 
and PDM-122, Hitachi-Aloka Medical Ltd., Japan) for the body, and thermo-stimulated luminescent 
ring dosimeters for extremities (Landauer, UK). Radiation contamination monitoring of staff, rooms, 
equipment and waste was carried out after each procedure using a scintillation monitor (Type 41/44A, 
Series 300 mini-monitor, ThermoScientific, USA). As 99mTc has a longer half-life (6.02 hours) than 18F 
(110 min) the radioactive waste storage requirements for CLI procedures are similar to standard SLNB 
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procedures. The time taken for the various stages of the procedure, i.e. from induction of anesthesia 
to recovery, were recorded. 
 
     Histopathology. Histopathological analysis was performed as per UK National guidelines: the WLE 
specimen was sliced at 2 mm intervals, and representative sections of the tumor and all 6 relevant 
margins were selected by the pathologist, processed, paraffin wax embedded and 3 to 4 micron 
sections were cut and stained with hematoxylin and eosin. Microscopic margin distance 
measurements were performed by a Consultant breast pathologist (S.E.P.). Microscopic invasive 
tumor size and whole tumor size (including DCIS extending from the main invasive mass) were also 
measured. Positive margins were defined as invasive cancer or DCIS <1 mm from the specimen 
surface. The histological margin distances were reported in increments of 1 mm, but margins more 
than 5 mm were reported as >5 mm. The pathologist was blinded to the interpretation of the CLI 
images. 
 
     Image analysis. All CLI and radiography images were analyzed postoperatively in order to provide 
a controlled and standardized analysis environment. Measurements of the mean radiance 
(photons/s/cm2/sr) were performed by drawing region-of-interests on the unprocessed CLI images. 
Region-of-interests were selected in areas showing increased signal intensity (‘tumor’) and no 
increased signal (‘tissue background’). Tumor-to-background ratios (TBRs) were calculated.  Gamma 
strikes were excluded from region-of-interest analysis. The tumor radiance from the sequential incised 
WLE images was fit to a monoexponential, to determine the radiance half-life.  
Assessment of margin status on CLI was performed on the incised WLE specimen images. 
The analysis was done independently by two experienced breast surgeons (AP and AK), and 
performed prior to analysis of the radiography images to prevent potential confirmation bias from a 
priori knowledge of the radiological margin status. Prior to analysis CLI images were processed by 
applying a median filter (filter size range 5 – 10, filter threshold range 10 – 15) and Gaussian filter 
(filter width: 1, filter threshold: 0.5). A stronger Gaussian filter (filter width: 4 or 5) was applied to 
images with a low TBR to increase the visibility of the tumor. The preoperative diagnostic information 
that would typically be available to the surgeon was provided including patient age, clinical, 
mammographic and ultrasound tumor size, screen detected (Y/N), and histological tumor type, grade 
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and receptor status on core biopsy. Per patient, a color image containing information on specimen 
orientation was shown together with a grey-scale image and Cerenkov image. All images were 
displayed on a standard computer monitor (23”, 1920 x 1080 pixels, 250 cd/m2 luminance). The grey-
scale image was overlaid with the Cerenkov signal to provide a fused image containing both functional 
and anatomical information. The leveling was set using the software’s default leveling, and manually 
adjusted based on the surgeon’s clinical judgment. Both surgeons then independently reported 
whether an elevated radiance from the tumor could be identified on CLI; in patients displaying an 
elevated tumor radiance the margin distance of the margins visible in the image was measured using 
the ruler function in the imaging software (Mirada XD3, Mirada Medical, Oxford, UK). The total time 
required to complete margin assessment was approximately 2 min per patient. As an exploratory 
outcome measure, tumor size was also measured. Upon completion of the measurements surgeons 
were asked whether, given the CLI image, they would have performed a cavity shaving had the image 
been available at the time of surgery. Surgeons also scored image quality on a 5-point Likert scale: 1 
= very poor – image not interpretable, 2 = poor but interpretable, 3 = fair, 4 = good, 5 = very good. 
Following CLI image analysis, specimen radiography image analysis was performed on a 
Coronis 3MP screen (20.8”, 1536 x 2048 pixels, 500 cd/m2 luminance) using standard GE PACS 
imaging software. Surgeons were presented with the same preoperative diagnostic information, but 
the images were shown in a different order to avoid potential sequential bias. The number of surgical 
marker clips was noted, and the reliability of specimen orientation assessed. If the orientation was 
considered reliable, the margin distance and tumor size on radiography was measured. Whether an 
additional cavity shaving would have been performed based on the radiography image was also 
noted.  
The final histopathology results of the surgically excised tissue were not available at the time 
of CLI and radiography image analysis, and could therefore not bias the surgeon’s assessment. 
 
     Statistics. Weighted Kappa coefficients were calculated to assess the agreement in margin 
distance between CLI and definitive histopathology, and to assess the inter-rater agreement between 
surgeons (‘irr’ package, version 3.2.2, R statistical software). A kappa coefficient (κ) greater than 0.75 
was considered good agreement (13). Agreement between histological tumor size and tumor size on 
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CLI and radiography respectively was assessed by calculating the mean difference in tumor size ± std, 
and intraclass correlation coefficients (ICC) (SPSS® version 23.0; IBM, Chicago).  
 
RESULTS 
Intraoperative imaging of WLE specimens  
A total of 22 patients were included in the study. The CLI results and postoperative histopathology 
results from the 12 patients included in the analysis dataset are shown in Table 1. The mean 
administered 18F-FDG activity was 295 ± 18 MBq (range 259 – 325). The mean time between 18F-FDG 
injection and WLE excision was 86 ± 26 min (range 50 – 146), and the mean time between 18F-FDG 
injection and commencement of CLI image acquisition was 118 ± 26 min (range 88 – 180).  
Tumor margin assessment was performed on incised WLE specimen images to allow for 
visualization of the tumor extent and to avoid image artifacts created by the monopolar diathermy. Ten 
of the 12 patients in the analysis dataset had elevated tumor radiance on CLI (Table 1). Mean tumor 
radiance and TBR in these 10 patients was 560 ± 160 photons/s/cm2/sr (range 308 – 871) and 2.41 ± 
0.54 (range 1.63 – 3.22). The half-life of the tumor radiance was 115.5 min, which is consistent with 
the 109.8-minute half-life of 18F. This concordance supports that the detected tumor radiance is 
Cerenkov luminescence from 18F-FDG. Mean radioactivity in the WLE specimen at the time of CLI 
imaging was 90 ± 48 kBq in patients with an elevated radiance; in the 2 patients without an elevated 
radiance radioactivity was 14 kBq and 19 kBq, respectively. 
In the 10 patients with elevated tumor radiance, a total of 60 margins could be assessed 
histologically, 26 margins were evaluable on specimen radiography, and 15 margins were assessable 
on CLI. Of the 45 histological margins that were not evaluable on CLI, 40 were not in the field-of-view 
of the CLI image, and 5 could not be assessed due to migration of the specimen orientation ink onto 
the margin edge, preventing optical margin interrogation. Eighteen of the 60 histological margins were 
not assessable on specimen radiography due to the inability to reliably orientate the specimen on the 
radiography image, and 16 margins were not in the image field-of-view. 
The margin distance from the 15 margins as measured on CLI and histopathology is shown in 
Table 1. Two margins measured between 1 and 5 mm on CLI and histopathology (Figs. 2 and 3); the 
remaining 13 margins were >5 mm by both modalities. There was good agreement between the 
histological margin distance and the margin distance on CLI as measured by both surgeon 1 and 
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surgeon 2, respectively (κ surgeon 1 = 0.76, κ surgeon 2 = 0.86). The agreement in margin distance 
between surgeons was also good (κ = 0.91).  
Five margins could be assessed on both CLI and specimen radiography, and all were >5 mm 
on both modalities, as well as histologically. An example of a CLI, radiography and histopathology 
image from a patient with >5 mm resection margin widths is shown in Fig. 4.  
Two patients (17%) had a positive margin on postoperative histopathological analysis; both 
were medial margins with DCIS <1 mm distant. These margins were not visible in the CLI image as 
specimen incision had only exposed the superior, inferior and posterior margins; the medial margin 
could therefore not be assessed. 
In 8 of the 10 patients tumor size could be measured on CLI, and compared to histopathology: 
the agreement is shown in Table 1. In 2 patients the orientation inks prevented measurement of tumor 
size on CLI. Invasive tumor size showed excellent agreement; mean difference for both surgeons 
combined was -0.84 ± 2.8 mm. ICC was 0.84 and 0.81 for surgeons 1 and 2, respectively. Whole 
tumor size was underestimated on CLI; mean difference for both surgeons combined was -4.7 ± 5.0 
mm. ICC was 0.65 and 0.69 for surgeons 1 and 2, respectively. Inter-rater agreement between 
surgeons was excellent (ICC = 0.97).  
The agreement between invasive tumor size on histopathology and on radiography was good; 
mean difference for both surgeons combined was 1.0 ± 3.1 mm. ICC was 0.56 and 0.58 for surgeons 
1 and 2, respectively. Whole tumor size was underestimated on radiography; mean difference for both 
surgeons combined was -5.2 ± 8.9 mm.  
CLI image quality in the 10 patients with successful CLI was scored as 4.3 (range 4 – 5) by 
both surgeons.  
 
Sentinel lymph node detection and 18F-FDG Cerenkov lymph node 
imaging  
SLNB was performed in 21 of the 22 patients; 1 patient underwent an ALND. SLNs were successfully 
identified in all 21 patients. A total of 43 SLNs were removed. The average number of SLNs per 
patient was 2 (range 1 – 4). Two of the 21 SLNB patients had macrometastatic SLNs.  
The mean gamma probe signal of the ‘hottest’ SLN per patient was 4991 ± 2521 counts per 
second (range 8500 – 170). The mean gamma probe signal of the ‘second hottest’ SLN was 2505 ± 
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2632 counts per second (range 7368 – 50). Mean axillary background signal, measured in 13 patients, 
was	192 ± 70 counts per second (range 55 – 270). This signal is lower than the 18F-FDG gamma 
probe cross-talk measured in the lead-in study (Supplemental Material), and is mainly due to the 
longer time between 18F-FDG injection and SLNB (mean 93 ± 34 min). A total of 7 nodes had a 
gamma probe signal below the background signal; 6 of these were blue. This indicates the importance 
of using the combined technique of radioisotope and blue dye in 18F-FDG CLI guided breast surgery, 
as low-uptake nodes may be missed if gamma probe detection is used alone. 	
All SLNB procedures were performed with the monopolar diathermy device and due to the 
observed image artifact from diathermy on CLI, the SLN images were uninterpretable.  
 
Radiation dose to staff  
A summary of the whole body effective radiation dose to primary personnel from all 22 procedures is 
shown in Table 2. Surgeons received the highest mean and maximum dose of 34 µSv and 74 µSv 
respectively. Mean duration of surgery was 39 ± 11 min (range 21 – 61) during which the surgeon was 
generally <0.5 meters from the patient. Mean radiation dose to the left and right hand of the surgeon 
was 126 ± 95 µSv (0 – 250) and 78 ± 75 µSv (0 – 200), respectively. Mean and maximum radiation 
dose received by the anesthetist standing at approximately 1 meter from the patient, with closer 
patient contact at the time of induction of anesthesia and at the end of the procedure, was 11 µSv and 
18 µSv, respectively. Surgical equipment had low levels of radioactive contamination, which was 
undetectable 1-3 days later. No staff members were found to be contaminated with radioactivity after 
the procedures.   
 
DISCUSSION 
This first-in-human study evaluated the feasibility of intraoperative 18F-FDG CLI for assessing tumor 
margin status in patients with invasive breast cancer undergoing BCS, and SLNB or ALND. Tumor 
margin assessment on CLI could be performed in 10 of the 12 patients in the analysis dataset, and 
there was strong agreement between CLI and definitive histopathology on margin width. An 
exploratory outcome measure assessed the correlation between tumor size on CLI and 
histopathology; the size on CLI and histopathology correlated well for invasive cancer, while whole 
tumor size (invasive with associated DCIS) was underestimated on CLI. Results from the radiation 
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monitoring program demonstrated that the procedure can be carried out safely while maintaining low 
radiation exposures to the staff involved. 
 In 2 patients margin assessment could not be performed because the tumors did not display 
elevated radiance on CLI. The absence of signal in these patients is probably due to the small tumor 
size, a factor known to be associated with lower 18F-FDG uptake (14), and the late time points at 
which these tumors were imaged (135 min and 180 min post 18F-FDG injection; the first and third 
longest injection-imaging time of all patients). Unsuccessful CLI imaging due to the absence of a 
detectable tumor signal highlights the importance of ongoing developments focused on improving 
detection sensitivity of camera systems to aid detection of tumors with low 18F-FDG uptake including 
lower grade tumors and DCIS (4).  
   Since its discovery in 2009, CLI has rapidly emerged as a powerful technique for cancer 
imaging. CLI is readily translatable to the clinic due to existing regulatory approval and widespread 
availability of PET imaging agents (15). In contrast, targeted fluorescence imaging requires prohibitive 
clinical development times and capital investment for regulatory and reimbursement approval of novel 
imaging drugs (16). Three clinical pilot studies of CLI have been published to date. These have 
focused on the use of CLI to image radiopharmaceutical uptake in the thyroid, CLI for non-invasive 
detection of nodal disease, and Cerenkov luminescence endoscopy to aid detection of cancerous 
lesions in the GI tract (17-19). To our knowledge, this is the first report of intraoperative CLI. Its high-
resolution, small size imaging equipment and minute-scale image acquisition (5 min) and image 
analysis (~2 min) times, make CLI of particular interest for image-guided surgery. The feasibility of 
intraoperative CLI as shown in this study in combination with the wide applicability of 18F-FDG across 
a range of solid cancers provides a stepping stone for clinical evaluation of this technology in other 
cancer types.  
 The low radiation exposure to staff found in this study is in accordance with previously 
reported exposure levels from 18F-FDG guided breast surgery procedures (20,21), and comparable to 
the radiation dose reported for interventional cardiology procedures (1 – 50 µSv) (22). The number of 
18F-FDG CLI-guided BCS procedures that could be performed in a routine clinical setting depends on 
the occupational limits on radiation exposure per country (Table 2). In the UK and US the occupational 
annual dose limit is 20 mSv (23) and 50 mSv (24), respectively. Good practice would dictate that the 
radiation exposure from a procedure should be kept As Low As Reasonable Achievable, i.e. well 
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below the dose limits. In practice in the UK, if a worker is likely to receive annually more than 6mSv 
they would be designated a classified worker, necessitating annual medical surveillance and longer 
term record keeping of their radiation exposure.  
 Image artifacts on CLI from tissue excised with the monopolar diathermy device prevented 
tumor margin assessment on intact WLE specimens and assessment of SLNs. Although the source of 
this ‘false-signal’ is not yet fully understood, current evidence from pre-clinical experiments points 
towards long-lived, thermally-induced chemiluminescence (25). Since the emission seems to be 
related to temperature, which can reach up to 250°C at the tip of the diathermy device, electrosurgical 
devices that operate at much lower temperatures are currently being tested (26). In addition to 
potentially facilitating margin assessment on intact WLE specimens, an advantage of low-temperature 
devices over monopolar diathermy is the reduced collateral tissue damage, which could also improve 
the accuracy of assessing tumor resection margins on histopathology (27).   
 Although CLI imaging of incised WLE specimens is feasible for assessing tumor margin 
status, this approach has some limitations over margin assessment on intact specimens. Firstly, 
migration of the wet pathology ink onto the margin edge immediately after specimen incision hinders 
margin interpretation with CLI. Methods to accelerate drying of inks by applying acetic acid to the 
painted tissue or by using fast drying inks may be solutions to this problem, but this has not been 
tested in this study. Secondly, in our institution specimen incision could only be performed through the 
posterior margin to ensure accurate postoperative histological assessment of radial margins. 
Consequently, only a limited number of margins could be assessed with CLI imaging per patient, and 
two histologically positive margins that were not visible in the CLI image were therefore missed. In 
order to assess more margins per patient specimen incision may be performed in multiple planes, but 
good communication between surgeons and pathologists is paramount in order to not compromise 
patient care. 
A randomized, controlled, multi-center clinical study is scheduled to commence in late 2016 to 
evaluate the effect of intraoperative 18F-FDG CLI on re-operation rate and Quality of Life in BCS 
(ClinicalTrials.gov identifier NCT02666079). The study will run across an anticipated 8 study sites in 
the UK and Germany and use the CE-marked LightPathTM Imaging System (Lightpoint Medical Ltd, 
UK).  The smaller field-of-view of 6 x 6 cm and improved imaging software may provide substantial 
improvements in sensitivity over the investigational CLI camera used in the present study. By 
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analyzing larger subgroups of patients with a range of tumor types (including DCIS), size, histological 
grades and hormone receptor status, further insight should be obtained into which breast-cancer 
patient populations may most benefit from CLI-guided surgery.  
 
CONCLUSION 
Intraoperative 18F-FDG CLI in BCS for invasive breast carcinoma is a promising and low-risk 
procedure. CLI imaging of incised WLE specimens provides high-resolution functional information that 
allows surgeons to accurately assess margin status with good correlation to gold-standard 
histopathological examination. Further work, focused on suppressing the optical signal from the 
monopolar diathermy device, will assist margin assessment on intact WLE specimens and potentially 
identification of SLN metastases on CLI. SLNB can be performed successfully during 18F-FDG CLI-
guided surgery by using 150 MBq 99mTc-nanocolloid and blue dye. Based on the results of this study a 
larger randomized controlled study is warranted to evaluate the impact of intraoperative 18F-FDG on 
re-operation rate and Quality of Life in BCS. 
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FIGURES WITH LEGENDS 
 
Figure 1: Investigational intraoperative CLI specimen camera. (A) Schematic diagram. Component 
labels: 1) EMCCD camera, 2) f/.95 lens, 3) Hinged reflex mirror, 4) Complementary metal-oxide-
semiconductor reference camera,  5) Specimen table, 6) Lead radiation shielding for EMCCD camera, 
7) Focal zone, 8) Fixed lens for reference camera, 9) Filter wheel, 10) LED RGB light array, 11) 
Specimen chamber. The purple line shows the optical paths for the EMCCD camera and the reference 
camera as determined by the angle of the reflex mirror. (B) Specimen chamber. The specimen table is 
placed on a parallelogram to facilitate accurate positioning of the specimen in the center of the image. 
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Figure 2: WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. 
(A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased 
signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean 
TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a 
cavity shaving would have been performed if the image had been available intraoperatively. The 
medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented 
assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen 
radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position 
of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined 
histopathology image from two adjacent pathology slides on which the posterior margin (bottom of 
image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin 
measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image).  
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Figure 3: WLE specimen from a patient with a grade 3, ER+/HER2-, NST carcinoma admixed with 
high grade DCIS. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov 
signal. An increased signal from the tumor is visible (white arrows); mean radiance is 406 ± 51 
photons/s/cm2/sr, mean TBR is 2.03. The posterior margin (outlined in blue) is 2 mm or 3 mm on CLI 
as measured by surgeons 1 and surgeon 2, respectively; both surgeons would have performed a 
cavity shaving. The medial margin (outlined in green) is >5 mm. (C) Specimen radiography image. All 
4 radial margins were >5 mm, and both surgeons indicated they would not have performed a cavity 
shaving. (D) Histopathology image showing the posterior margin (left side of image) and part of the 
tumor (open arrows). The posterior margin was 5 mm distant histologically (double arrow).  
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Figure 4: WLE specimen from a patient with a grade 3, ER+/HER2-, NST carcinoma admixed with 
high grade DCIS. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov 
signal. An elevated signal (white arrow) from the tumor can be seen. Mean radiance is 637 ± 47 
photons/s/cm2/sr; mean TBR is 1.63. Both surgeons measured the posterior margin (outlined in blue), 
medial margin (outlined in green) and lateral margin (outlined in red) distances as >5 mm; a cavity 
shaving would not have been performed based on the CLI image. (C) Specimen radiography image. 
All 4 radial margins were >5 mm as measured by both surgeons and did not prompt resection of cavity 
shave margins (D) Histopathology image from large-format pathology block. The tumor is >5 mm from 
the posterior margin (solid arrow), medial margin (dashed arrow) and lateral margin (not visible in 
image).  
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Table 1: CLI and postoperative histopathology results for each patient in the analysis dataset.  
Patient Tumor 
type1 
Histologic 
grade 
invasive 
(1 – 3) 
ER/HER2 
status of 
invasive 
cancer 
(Pos/Neg)2 
Mean tumor  
radiance 
(photons/s/cm2/sr) 
TBR3 Margin distance 
CLI surgeon 1, 27 
(mm) 
Margin 
distance 
histopath5 
(mm) 
Tumor size 
CLI surgeon 1, 27 
(mm) 
Invasive 
tumor size 
histopath8 
(mm) 
Whole 
tumor size 
histopath8 
(mm) 
1 NST  DCIS 2 Pos/Neg -
4 - - - - 13 13 
2 NST  DCIS 3 Neg/Pos 453.59 2.34 6, 6 >5 *
6 22 22 
3 NST 3 Neg/Neg 871.16 3.22 2, 2 28, 30 
3 
>5 20, 18 20 20 
4 NST  DCIS 3 Neg/Neg -
4 - - - - 14 14 
5 NST  DCIS 3 Pos/Neg 405.76 2.03 2, 3 5 18, 18 20 20 
6 ILC 2 Pos/Neg 544.04 2.44 9, 9 >5 20, 19 22 22 
7 NST 3 Pos/Neg 667.47 2.72 10, 11 >5 *6 25 25 
8 NST  DCIS 2 Pos/Neg 308.30 1.63 
6, 8 
16, 15 
>5 
>5 19,19 15 35 
9 NST  DCIS 3 Pos/Neg 593.93 3.08 
14, 13 
6, 7 
>5 
>5 14, 15 18 19 
10 NST  DCIS 3 Pos/Neg 648.29 2.46 8, 8 >5 22, 22 19 29 
11 NST  DCIS 2 Pos/Neg 466.03 2.54 15, 14 >5 13, 11 13 13 
12 NST  DCIS 3 Pos/Neg 637.08 1.63 
9, 9 
30, 31 
22, 22 
>5 
>5 
>5 
12, 10 14 14 
1. NST: invasive carcinoma of ductal/no special type, DCIS: ductal carcinoma in situ, ILC: invasive lobular carcinoma 
2. Pos: positive, Neg: negative 
3. Tumor-to-background ratio 
4. No elevated tumor radiance on CLI  
5. Histopath: histopathology 
6. Presence of orientation inks prevented measuring tumor size on CLI. 
7. Margin distance and tumor size are shown for surgeon 1 and 2, respectively 
8. The histopathological tumor size displayed in the table is the tumor size measured in the same direction as the tumor size measurement on CLI. In patient 3, 11 and 
12 the largest invasive and whole tumor size (i.e. extent of DCIS and invasive cancer) was measured in a different direction, and was 32 mm, 33 mm and 12 mm, 
respectively  
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Table 2: Measured effective radiation doses by occupation from 22 surgical procedures. 
 
Staff Group N1 Mean Effective Dose per procedure ± std (µSv) 
Range 
(µSv) 
Estimated number of procedures per 
individual per year2 
Estimated number of procedures per 
individual per year2 
ICRP3 (20 mSv annual limit) USNRC4 (50 mSv annual limit) 
Surgeon 46 34 ± 15 8 – 74 270 676 
Anesthetist 22 11 ± 5 0 – 18 1111 2778 
NM technologist 22 9 ± 4 1 – 15 1333 3333 
Anesthetist assistant 22 6 ± 3 0 – 11 1818 4545 
Trial Co-coordinator 21 5 ± 2 1 – 10 2000 5000 
Recovery Nurse 43 4 ± 3 0 – 14 1429 3571 
Scrub Nurse 22 2 ± 1 0 – 5 4000 10000 
Periphery Nurse 23 1 ± 1 0 – 4 5000 12500 
Research fellow 36 1 ± 2 0 – 13 1538 3846 
Ward Nurse 15 0 0 – 1 20000 50000 
Tissue Biobank Practitioner  14 0 0 – 1 20000 50000 
1. N = number of measurements 
2. Based on maximum Effective Dose per procedure per staff group 
3. ICRP: International Commission on Radiological Protection 
4. USNRC: United States Nuclear Regulatory Commission
